Navigation Links
Vaccinex, Inc. Awarded Three Qualifying Therapeutic Discovery Project (QTDP) Grants Under the Patient Protection and Affordable Care Act of 2010 (PPACA)
Date:11/1/2010

ROCHESTER, N.Y., Nov. 1, 2010 /PRNewswire/ -- Vaccinex, Inc. announced today that it has been awarded three grants by the United States government under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the development of the company's three lead therapeutic monoclonal antibodies, VX15, VX5 and VX35.  The QTDP grant program provides support for innovative projects that are determined by the U.S. Department of Health and Human Services to have reasonable potential to result in a new therapy, reduce health care costs, or significantly advance the goal of curing cancer.  

(Logo: http://photos.prnewswire.com/prnh/20101101/NY92716LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20101101/NY92716LOGO)

Commenting on the grant awards, Dr. Maurice Zauderer, President & CEO, said, "We are very appreciative of the recognition and support provided by these awards for innovative Vaccinex projects that could advance the treatment of cancer and autoimmune diseases, and also provide significant economic benefits to our community."

The three different Vaccinex projects represent novel approaches to inhibit invasive tumor growth and to treat multiple sclerosis and other neurodegenerative diseases.  Vaccinex expects to begin clinical trials of its lead therapeutic antibodies in cancer and multiple sclerosis in early 2011.

Vaccinex, Inc.

Founded in 1997 and located in Rochester, NY, Vaccinex, Inc. is a privately held biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies and vaccines to treat serious diseases with unmet needs, including cancer, multiple sclerosis, and other autoimmune diseases.   Website: www.vaccinex.com.  


'/>"/>
SOURCE Vaccinex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million
2. Dr. Yong Shi awarded NSF grant
3. eGenomics Awarded First U.S. Patent Covering Rapid DNA Sequencing Technology Platform to Control Hospital-Acquired Infections
4. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
5. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
6. GeneGo Is Awarded NCI Grant for Development of Systems Biology Database and Tools for Nutrition in Cancer in Collaboration with the FDA
7. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
8. SpectraScience Awarded Patent for Its Optical Biopsy System and Methods for Tissue Diagnosis
9. Caprion Awarded US $12.9M Infectious Disease Biomarker Research Contract
10. Integrated BioTherapeutics Awarded NIAID Contract For Up to $65 Million for Development of a Vaccine against Ebola and Marburg Viruses
11. SENOMYX CO-FOUNDER AND SCIENTIFIC ADVISORY BOARD MEMBER ROGER TSIEN, PH.D., AWARDED NOBEL PRIZE IN CHEMISTRY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont ... today that they have entered into a multiyear collaboration to identify and characterize ... with additional tools for gene editing across all applications. , Under the terms ...
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS ... the addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s US ... absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical applications. ...
(Date:10/12/2017)... CA (PRWEB) , ... October ... ... (https://www.onramp.bio/ ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed ... bioinformatics complexity. Named in honor of pioneering researcher Rosalind Franklin, who made ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of ... performing systematic gain-of-function studies. , This complement to loss-of-function studies, such as ...
Breaking Biology Technology:
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/4/2017)... --  EyeLock LLC , a leader of iris-based identity ... and Trademark Office (USPTO) has issued U.S. Patent No. ... iris image with a face image acquired in sequence ... th issued patent. "The issuance ... multi-modal biometric capabilities that have recently come to market ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
Breaking Biology News(10 mins):